Drug – bio-affecting and body treating compositions – Enzyme or coenzyme containing – Hydrolases
Reexamination Certificate
1999-02-05
2001-08-28
Wortman, Donna C. (Department: 1648)
Drug, bio-affecting and body treating compositions
Enzyme or coenzyme containing
Hydrolases
C424S094650, C514S025000, C514S021800, C514S027000
Reexamination Certificate
active
06280728
ABSTRACT:
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is entitled to priority pursuant to 35 U.S.C. §119 to German patent application 198 04 742.8, filed Feb. 6, 1998.
BACKGROUND OF THE INVENTION
The present invention relates to the use of at least one hydrolytic enzyme and at least one flavonoid for the treatment of diseases caused by hepatitis C viruses.
Hepatitis is an inflammation of the liver, which can arise on account of various causes. The acute forms of hepatitis are mostly caused by viruses. At present, six different types of hepatitis virus are known (A-E and G). Hepatitis C is a viral disease in which persistence of the hepatitis C virus or chronic hepatitis can ensue. This chronic hepatitis C develops in about 50% of the infected individuals. About 20% of the individuals suffering from chronic hepatitis C show histological signs of hepatic cirrhosis. In addition to this, hepatitis C virus probably plays an important part in the development of hepatocellular carcinomas. These complications often lead to death. The medicinal treatment of hepatitis C is still in the experimental stage. Usually, individuals suffering from chronic hepatitis C are treated by dietetic measures in order to spare the hepatic metabolism. The use of &agr;-interferon and ribavarin is also considered. However, these agents often show undesired side-effects, and moreover both are very expensive. Furthermore, both preparations show a lasting effect in only about 20% of the patients.
SUMMARY OF THE INVENTION
The present invention was therefore based on the technical problem of providing further substances or combinations which show an improved effect in the treatment of diseases caused by hepatitis C virus.
This task is achieved by the use of at least one hydrolytic enzyme and at least one flavonoid.
REFERENCES:
Kabil et al., Oral enzyme therapy in hepatitis C patients. International Journal of Tissue Reactions 19(1/2): 97-98, 1997.*
Stedman's Medical Dictionary, Williams & Wilkins, 1995.*
G. Stauder, et al., “Oral Enzyme Therapy In Hepatitis C Patients”, International Journal of Immunotherapy XIII(3/4) pp. 153-158 (1997)—published Mar. 1998.
Ransberger Karl
Stauder Gerhard
Akin Gump Strauss Hauer & Feld L.L.P.
Mucos Pharma GmbH & Co.
Wortman Donna C.
LandOfFree
Treatment of hepatitis C virus infection using a protease... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of hepatitis C virus infection using a protease..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of hepatitis C virus infection using a protease... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2442430